'More balanced' appeals might make NICE nicer, says industry
This article was originally published in Scrip
The panel that hears appeals against guidance from NICE, the health technology appraisal body for England and Wales, will become more independent from the institute, according to England's Department of Health. The move gives companies the chance of more "balanced" hearing, says the Association of the British Pharmaceutical Industry. However, it does not make it any easier for them to actually get a hearing in the first place as the department has no plans to widen the grounds for appeal.
You may also be interested in...
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.